Clinical

Dr Lopes provides insights into payer considerations when navigating geographic atrophy treatment pathways.

Drs Lally and Khanani expand on key takeaways from the GATHER1 and GATHER2 studies.

Dr Michos examines a controlled trial focusing on co-payment elimination and its effects on cardiovascular outcomes for low-income adults.

A study explored outcomes among patients living with newly diagnosed eosinophilic esophagitis (EoE) who demonstrated lack of histological response following proton pump inhibitor (PPI) treatment.

The use of active surveillance for indolent prostate cancer cases continues to rise in the United States, but rates of use are lower in minority groups, low-income groups, and patients in rural areas, a recent study found.

The data show how disease-modifying therapies are changing outcomes for children with spinal muscular atrophy (SMA), a rare neuromuscular disease.

In his closing thoughts, Dr Marshall shares final takeaways from the 2023 ASCO GI Cancers Symposium.

Lack of knowledge about how skin conditions present on lightly pigmented skin has resulted in diagnostic delays, underassessment, and an impact on quality of life for patients with skin of color.

The findings from this single-center cross-sectional study, say the researchers, suggest that IL-6 signaling may be a promising target for the treatment of patients with glutamic acid decarboxylase (GADA)–induced autoimmune epilepsy.

Using data from the PROVE-HF study, investigators conducted a subanalysis of outcomes among patients receiving sacubitril/valsartan who did and did not have ischemic heart disease.

A new case series highlights characteristics and challenges of this subgroup of patients with myasthenia gravis (MG).

Retinopathy of prematurity (ROP) that occurs in preterm babies can progress fast, which requires quick decisions early about treatment, explained Darius M. Moshfeghi, MD, chief, Retina Division, and professor at the Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine.

A review of cases involving Jehovah’s Witnesses found many modalities can be successfully deployed to treat thrombotic thrombocytopenic purpura (TTP).

More information is needed to better understand variations in how the drug affects individual patients.

Immunotherapies are an important breakthrough in cancer treatment, but little is known about which practices adopt the therapy or the pace at which they do so.

The current study, which showed that cannabidiol (CBD) blocked signals carried by the molecule lysophosphatidylinositol in neurons, offers new insights into these mechanisms.

Researchers collected physical function measures and blood samples from 24 patients enrolled in a 16-week trial of at-home aerobic and/or resistance exercise.

A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small-cell lung cancer (NSCLC) treated with cemiplimab.

Physicians may be able to better identify patients with chronic cough using the combination of 2 coughing tests.

The GATHER1 and GATHER2 studies are highlighted.

Medical experts recap the DERBY and OAKS studies.

Hypercholesterolemia impact on cardiovascular outcomes is explored by a key opinion leader.

Because biologics are used to treat both conditions, researchers hypothesized they may be helpful to prevent psoriatic arthritis (PsA).

James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains the antibody subtypes associated with this rare neuromuscular disease.

Chimeric antigen receptor (CAR) T-cell therapies have shown efficacy and safety for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but barriers to referral may obstruct patient access to them.

A secondary analysis of the phase 3 TOURMALINE-MM4 trial found that ixazomib as postinduction maintenance therapy for multiple myeloma produced a progression-free survival (PFS) benefit vs a placebo across age and frailty subgroups.

Perfluorohexyloctane (NOV03) was able to reduce the signs and symptoms of dry eye disease (DED) when compared with hypotonic saline control and was well tolerated.

The SPOTLIGHT study results presented at the 2023 ASCO GI Cancers Symposium are explored by Dr Marshall.

Each trial extension has added new and more data and a better understanding of how ruxolitinib cream treats vitiligo in the long term, explained John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School.

A multidisciplinary approach and symptom management are both vital components of home care to provide continuity of care after cardiac surgery because they decrease symptoms and readmissions to the hospital and increase self-efficacy.